- Home
- NBY vs KTTA Comparison
NBY vs KTTA Comparison
Compare NBY & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBY
- KTTA
- Stock Information
- Founded
- NBY 2000
- KTTA 2020
- Country
- NBY United States
- KTTA United States
- Employees
- NBY N/A
- KTTA 8
- Industry
- NBY
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- NBY
- KTTA Health Care
- Exchange
- NBY Nasdaq
- KTTA Nasdaq
- Market Cap
- NBY 2.8M
- KTTA 2.6M
- IPO Year
- NBY 2007
- KTTA 2021
- Fundamental
- Price
- NBY $0.64
- KTTA $3.30
- Analyst Decision
- NBY Strong Buy
- KTTA
- Analyst Count
- NBY 1
- KTTA 0
- Target Price
- NBY $0.85
- KTTA N/A
- AVG Volume (30 Days)
- NBY 502.1K
- KTTA 37.8K
- Earning Date
- NBY 03-25-2025
- KTTA 03-28-2025
- Dividend Yield
- NBY N/A
- KTTA N/A
- EPS Growth
- NBY N/A
- KTTA N/A
- EPS
- NBY N/A
- KTTA N/A
- Revenue
- NBY $13,844,000.00
- KTTA N/A
- Revenue This Year
- NBY N/A
- KTTA N/A
- Revenue Next Year
- NBY $17.31
- KTTA N/A
- P/E Ratio
- NBY N/A
- KTTA N/A
- Revenue Growth
- NBY 15.40
- KTTA N/A
- 52 Week Low
- NBY $0.36
- KTTA $2.03
- 52 Week High
- NBY $9.10
- KTTA $9.25
- Technical
- Relative Strength Index (RSI)
- NBY 49.67
- KTTA 30.89
- Support Level
- NBY $0.60
- KTTA $2.38
- Resistance Level
- NBY $0.84
- KTTA $2.62
- Average True Range (ATR)
- NBY 0.07
- KTTA 0.17
- MACD
- NBY -0.01
- KTTA -0.03
- Stochastic Oscillator
- NBY 26.79
- KTTA 12.28
About NBY NovaBay Pharmaceuticals Inc.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia.